Form 4: QuidelOrtho Director Kenneth Widder Receives Significant Equity Grants as Part of Compensation

QuidelOrtho Corp. Director Kenneth J. Widder was granted and converted a total of 10,633 Restricted Stock Units (RSUs) on May 29, 2025, as part of his compensation for Board service.

Summary

• Kenneth J. Widder, a Director of QuidelOrtho Corp. (QDEL), reported changes in his beneficial ownership of company securities.
• On May 29, 2025, Mr. Widder acquired 6,829 Restricted Stock Units (RSUs) as an equity grant, which are scheduled to vest on May 29, 2026.
• Additionally, on the same date, Mr. Widder acquired 2,926 RSUs that were converted in lieu of cash payments for certain retainer and Board of Director service-related fees under a deferred compensation program.
• These converted RSUs have a specific vesting schedule: 731 shares vested on May 29, 2025; 731 shares will vest on August 29, 2025; 732 shares will vest on November 29, 2025; and 732 shares will vest on February 28, 2026.
• An additional 878 RSUs were acquired as a 'Premium' grant on May 29, 2025, also related to the deferred compensation program, with vesting details tied to the program's schedule.
• Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
• Following these transactions, Kenneth J. Widder directly beneficially owns 6,829 RSUs from the equity grant, 2,926 RSUs from the conversion, and 878 RSUs from the premium grant, totaling 10,633 RSUs.

Sentiment

Score: 6

Explanation: The document reports routine compensation for a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. There are no negative implications or unexpected events reported.

Positives

• The granting of Restricted Stock Units (RSUs) to a director aligns their interests with those of the shareholders, as the value of their compensation is tied to the company's stock performance.
• The use of a deferred compensation program for non-employee directors can be a positive governance practice, allowing directors to defer income and potentially increase their long-term equity stake in the company.

Future Outlook

The future outlook involves the vesting of the granted Restricted Stock Units, with the equity grant vesting on May 29, 2026, and the converted/premium units vesting in tranches through February 28, 2026.

Industry Context

The practice of compensating non-employee directors with equity, such as Restricted Stock Units, is a common and widely accepted practice across various industries, including the healthcare diagnostics sector where QuidelOrtho operates. This method is often preferred over cash-only compensation to align director incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Compensating non-employee directors with equity awards like Restricted Stock Units (RSUs) is a standard practice across publicly traded companies, including those in the medical diagnostics and life sciences sectors, such as Danaher Corporation, Abbott Laboratories, and Thermo Fisher Scientific, which also utilize equity-based compensation to align director interests with company performance.
• The use of deferred compensation programs for directors, allowing them to receive equity in lieu of cash, is also a common governance practice aimed at increasing director ownership and commitment, comparable to programs seen at many S&P 500 companies.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The vesting of the 6,829 Restricted Stock Units on May 29, 2026.
• The subsequent vesting tranches of the 2,926 converted Restricted Stock Units on August 29, 2025, November 29, 2025, and February 28, 2026.
• The release of vested restricted stock units according to the elected deferral schedule for the converted and premium units.

Key Dates

Keywords

QuidelOrtho, QDEL, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Equity Grant, Deferred Compensation, Beneficial Ownership